GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials
In in vitro studies GLP-1R- agonists have been found to modulate immune responses
Common issues include nausea and diarrhea, but complications can also extend to conditions such as gastroesophageal reflux disease, gastroparesis (paralysis of the stomach), and colonic inflammation
A butyrate supplement : Our choice for the best butyrate supplement is BodyBio Calcium Magnesium Butyrate
GLP-1 receptor agonists e.g., semaglutide, liraglutide commonly cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation, less common risks include pancreatitis, gallbladder disease, and hypoglycemia mainly with insulin sulfonylureas
List conservative efforts tried: supervised weight management, specific exercise programs, for example, three months of supervised gym-based resistance training three times per week, compression therapy, physical therapy, medications, or manual lymphatic drainage
